)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Akari Therapeutics
Akari Therapeutics (AKTX) investor relations material
Akari Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary10 Jul, 2026
Company overview and business model
Focuses on developing next-generation antibody-drug conjugates (ADCs) using proprietary cancer-killing toxins as payloads, aiming to improve efficacy and safety over current ADC therapies.
Lead product candidate, AKTX-101, targets Trop2 in solid tumors and is in preclinical development, with a Phase 1 trial planned by mid-2027.
Pipeline includes AKTX-102, a CEACAM5-directed ADC, leveraging the same novel payload platform.
No commercial products or product revenue to date; business activities have focused on R&D and capital raising.
Financial performance and metrics
Has a history of operating losses and has not generated product revenue.
Ongoing operations depend on raising substantial additional capital for R&D and infrastructure.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of ADSs by selling shareholders; proceeds from warrant exercises (if any, up to $16.5 million) will be used for R&D, general/admin expenses, and working capital.
Pending use, proceeds will be invested in short-term, interest-bearing, investment-grade securities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Akari Therapeutics
- Resale registration covers nearly 6 million ADSs from private placements and warrants.AKTX
Registration filing8 Jul 2026 - Novel ADC platform with immune-activating PH1 payload shows strong preclinical synergy with checkpoint inhibitors.AKTXWebull Corporate Connect: Virtual Biotech Investment Webinar8 Jul 2026
- Pre-revenue biotech registers resale of 5.99M ADSs; proceeds from warrants to fund R&D.AKTXRegistration filing2 Jul 2026
- Preclinical oncology firm seeks up to $25M via ADS sales to fund R&D, with high dilution risk.AKTXRegistration filing26 Jun 2026
- Comprehensive AGM proxy covers governance, compensation, and major share issuance proposals.AKTXProxy filing4 Jun 2026
- Comprehensive AGM proxy covers governance, compensation, and major capital authorizations.AKTXProxy filing22 May 2026
- Q1 2026 net loss surged to $14.5M due to major impairment charges; urgent funding needed.AKTXQ1 202619 May 2026
- Highly dilutive best efforts offering seeks up to $6.7M for oncology R&D and operations.AKTXRegistration filing8 May 2026
- Net loss decreased to $17.3M in 2025; cash runway into April 2026, further funding required.AKTXQ4 202530 Mar 2026
Next Akari Therapeutics earnings date
Q2 202618 Aug, 2026
Akari Therapeutics
Next Akari Therapeutics earnings date
Q2 202618 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage